

DAFTAR PUSTAKA

- AIRTUM Working Group, CCM, AIEOP Working Group. *Italian cancer figures, report 2012: Cancer In Children And Adolescents*. Epidemiol Prev n.d.;37:1–225.
- Al-Salam S, Sharma C, Afandi B, Dahmani KA, Al-Zahrani AS, Shamsi AA, Kaabi JA. *BRAF and KRAS mutations in papillary thyroid carcinoma in the United Arab Emirates*, PLoS ONE 15(4): e0231341. <https://doi.org/10.1371/journal.pone.0231341>
- Albarel F, Conte-Devolx B, Oliver C. From nodule to differentiated thyroid carcinoma: contributions of molecular analysis in 2012. Ann Endocrinol (Paris). 2012 Jun;73(3):155-64. DOI: 10.1016/j.ando.2012.03.002
- Angell Trevor E. *RAS-positive thyroid nodules*. Curr Opin Endocrinol Diabetes Obes 2017, 24:000–000. DOI:10.1097/MED.0000000000000354
- Bhattacharyya N. *A Population-Based Analysis Of Survival Factors In Differentiated And Medullary Thyroid Carcinoma*. Otolaryngol Head Neck Surg 2003;128:115–23. doi:10.1067/mhn.2003.2
- Bae Ja-Seong, Choi SK, Jeon S, Kim Y, Lee S, Lee YS, Jung CK. *Impact of NRAS Mutations on the Diagnosis of Follicular Neoplasm of the Thyroid*. International Journal of Endocrinology Volume 2014, Article ID 289834, 7 pages. <http://dx.doi.org/10.1155/2014/289834>
- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. *Global Cancer Statistics 2018: GLOBOCAN Estimates Of Incidence And Mortality*

Worldwide For 36 Cancers In 185 Countries. CA Cancer J Clin
2018;68:394–424. doi:10.3322/caac.21492.

Booguski MS, McCormick F. Proteins regulating Ras and its relatives. Nature
volume 366, pages 643–654 (1993).

Brown AP, Chen J, Hitchcock YJ, Szabo A, Shrieve DC, Tward JD. *The Risk Of
Second Primary Malignancies Up To Three Decades After The
Treatment Of Differentiated Thyroid Cancer.* J Clin Endocrinol Metab
2008;93:504–15. doi:10.1210/jc.2007-1154.

Bychkov A., 2019, AJCC /TNM staging. PathologyOutlines.com

Clinkscales W, Ong A, Nguyen S, Harruff EE, Gillespie MB. *Diagnostic Value of
RAS Mutations in Indeterminate Thyroid Nodules: Systematic Review
and Meta-analysis.* Otolaryngology–Head and Neck Surgery 1–8. DOI:
10.1177/0194599816685697

Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, et al. *Revised
American Thyroid Association Management Guidelines for Patients
with Thyroid Nodules and Differentiated Thyroid Cancer.* Thyroid
2009;19:1167–214. doi:10.1089/thy.2009.0110.

Duan H, Liu X, Ren X, Zhang H, Liang Z. *Mutation profiles of follicular thyroid
tumors by targeted sequencing.* Diagnostic Pathology (2019) 14:39.
<https://doi.org/10.1186/s13000-019-0817-1>

Galuppini F, Pennelli G, Rugge M. *The Rising Incidence Of Papillary Thyroid
Cancer: More Cancers Or More Assessments?* Indian J Cancer
2019;56:183–4. doi:10.4103/ijc.IJC_483_18.



Goodarzi, Moslem A, Feizhadad H, Jarrahi AM, Adineh HA, Sohrabivafa M, et al.

Epidemiology, Incidence And Mortality Of Thyroid Cancer And Their Relationship With The Human Development Index In The World: An Ecology Study In 2018. Adv Hum Biol 2019;9:162. doi:10.4103/AIHB.AIHB_2_19.

Gupta N., Dasyam AK, Carty SE, Nikiforova MN, Ohori NP, Armstrong M, Yip

L, et al. *RAS Mutations in Thyroid FNA Specimens Are Highly Predictive of Predominantly Low-Risk Follicular-Pattern Cancers.* Clin Endocrinol Metab, May 2013, 98(5):E914 –E922. doi: 10.1210/jc.2012-3396

Haugen Bryan R, Alexander Erik K, Bible Keith C, Doherty Gerard M, Mandel

Susan J, Nikiforov Yuri E, Furio Pacini, Randolph Gregory W, Sawka Anna M, Schlumberger Martin, Schuff Kathryn G., Sherman Steven I, Sosa Julie Ann, Steward David L, Tuttle R. Michael, Wartofsky Leonard. *2015 America Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer.* THYROID Volume 26, Number 11,2016. doi: 10.1089/thy.2015.0020.

Hartmann JT, Haap M, Kopp H-G, Lipp H-P. *Tyrosine Kinase Inhibitors - A Review*

On Pharmacology, Metabolism And Side Effects. Curr Drug Metab 2009;10:470–81.

Hong DS, Cabanillas ME, Wheler J, et al. *Inhibition of the Ras/Raf/MEK/ERK and*

RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary

and differentiated thyroid malignancies. J Clin Endocrinol Metab .
2011 Apr;96(4):997-1005. doi: 10.1210/jc.2010-1899. Epub 2011 Feb
2.

Huang S-F, Chien H-T, Cheng S-D, Chuang W-Y, Liao C-T, Wang H-M. *EGFR Copy Number Alterations In Primary Tumors, Metastatic Lymph Nodes, And Recurrent And Multiple Primary Tumors In Oral Cavity Squamous Cell Carcinoma. BMC Cancer* 2017;17. doi:10.1186/S12885-017-3586-9.

Hughes DT, Haymart MR, Miller BS, Gauger PG, Doherty GM. *The Most Commonly Occurring Papillary Thyroid Cancer in the United States Is Now a Microcarcinoma in a Patient Older than 45 Years. Thyroid* 2011;21:231–6. doi:10.1089/thy.2010.0137.

Kilfoy BA, Devesa SS, Ward MH, Zhang Y, Rosenberg PS, Holford TR, et al. *Gender Is An Age-Specific Effect Modifier For Papillary Cancers Of The Thyroid Gland. Cancer Epidemiol Biomarkers Prev* 2009;18:1092–100. doi:10.1158/1055-9965.EPI-08-0976.

Konturek A, Barczyński M, Nowak W, Richter P. *Prognostic Factors In Differentiated Thyroid Cancer - A 20-Year Surgical Outcome Study. Langenbeck's Arch Surg* 2012;397:809–15. doi:10.1007/s00423-011-0899-z.

Krassas GE, Pontikides N. *Gonadal Effect Of Radiation From 131I In Male Patients With Thyroid Carcinoma. Arch Androl n.d.;51:171–5.*

La Vecchia C, Malvezzi M, Bosetti C, Garavello W, Bertuccio P, Levi F, et al.

Thyroid Cancer Mortality And Incidence: A Global Overview. Int J Cancer 2015;136:2187–95. doi:10.1002/ijc.29251.

Lloyd, R.V., Osamura, R.Y., Klöppel, G., Rosai, J., International Agency for Research on Cancer, 2017. WHO Classification of Tumours of Endocrine Organs, IARC WHO Classification of Tumours Series. International Agency for Research on Cancer.

Machens HG, Kaun M, Lange T, Egbers HJ, Wnzi MW, Paech A, Reichert B, Mailander P. Clinical impact of operative multidisciplinary for severe defect injuries of the lower extremity. Handchir Mikrochir Plast Chir. 2006 Dec;38(6):403-16. doi: 10.1055/s-2006-955892.

Mao Y, Xing M. *Recent Incidences And Differential Trends Of Thyroid Cancer In The USA*. Endocr Relat Cancer 2016;23:313–22. doi:10.1530/ERC-15-0445.

McIver B, Hay ID, Giuffrida DF, Dvorak CE, Grant CS, Thompson GB, et al. *Anaplastic Thyroid Carcinoma: A 50-Year Experience At A Single Institution*. Surgery 2001;130:1028–34. doi:10.1067/msy.2001.118266.

McLeod DS, Sawka AM, Cooper DS. *Controversies In Primary Treatment Of Low-Risk Papillary Thyroid Cancer*. Lancet 2013;381:1046–57. doi:10.1016/S0140-6736(12)62205-3.



Moura MM, Cavaco BM, Leite V. *RAS proto-oncogene in medullary thyroid carcinoma*. *Endocr Relat Cancer*. 2015 Oct;22(5):R235-52. doi: 10.1530/ERC-15-0070.

Myers MB, McKim KL, Parsons BL. *A subset of papillary thyroid carcinomas contain KRAS mutant subpopulations at levels above normal thyroid*. *Mol Carcinog*. 2014 Feb;53(2):159-67. DOI: 10.1002/mc.21953

Patel A, Jhiang S, Dogra S, Terrell R, Powers PA, Fenton C, et al. *Differentiated Thyroid Carcinoma That Express Sodium-Iodide Symporter Have A Lower Risk Of Recurrence For Children And Adolescents*. *Pediatr Res* 2002;52:737–44. doi:10.1203/00006450-200211000-00021.

Pellegriti G, Frasca F, Regalbuto C, Squatrito S, Vigneri R. *Worldwide Increasing Incidence of Thyroid Cancer: Update on Epidemiology and Risk Factors*. *J Cancer Epidemiol* 2013;2013:1–10. doi:10.1155/2013/965212.

Rahbari R, Zhang L, Kebebew E. *Thyroid Cancer Gender Disparity*. *Futur Oncol* 2010;6:1771–9. doi:10.2217/fon.10.127.

Riley RD, Hayden JA, Steyerberg EW, Moons KGM, Abrams K, Kyzas PA, et al. *Prognosis Research Strategy (PROGRESS) 2: Prognostic Factor Research*. *PLoS Med* 2013;10. doi:10.1371/journal.pmed.1001380.

Rodriguez-antona C, Taron M. *Pharmacogenomic biomarkers for personalized cancer treatment*. *Journal of Internal Medicine* Volume 277, Issue 2 p. 201-217. <https://doi.org/10.1111/joim.12321>

Schlessinger J. *Cell Signaling By Receptor Tyrosine Kinases*. *Cell* 2000;103:211–25. doi:10.1016/s0092-8674(00)00114-8.

- Sciuto R, Romano L, Rea S, Marandino F, Sperduti I, Maini CL. *Natural History And Clinical Outcome Of Differentiated Thyroid Carcinoma: A Retrospective Analysis Of 1503 Patients Treated At A Single Institution.* Ann Oncol Off J Eur Soc Med Oncol 2009;20:1728–35. doi:10.1093/annonc/mdp050.
- Shaha AR, Shah JP, Loree TR. *Risk Group Stratification And Prognostic Factors In Papillary Carcinoma Of Thyroid.* Ann Surg Oncol 1996;3:534–8.
- Sharma A, Jasim S, Reading CC, Ristow KM, Villasboas Bisneto JC, Habermann TM, et al. *Clinical Presentation and Diagnostic Challenges of Thyroid Lymphoma: A Cohort Study.* Thyroid 2016;26:1061–7. doi:10.1089/thy.2016.0095.
- Sherman SL, Cohen EW, Schoffski P, Elise R, Schlumberger M. Efficacy of cabozantinib (Cabo) in medullary thyroid cancer (MTC) patients with RAS or RET mutations: Results from a phase III study. Clinical trial information: NCT00704730
- Siegel RL, Miller KD, Jemal A. *Cancer statistics of American 2019.* CA Cancer J Clin 2019. doi:10.3322/caac.21551.
- Smallridge Robert C, Ain Kenneth B, Asa Sylvia L, Bible Keith C, Brierly James D, Burman Kenneth D, Kebebew Electron, Lee Nancy Y, Nikiforov Yuri E, Rosenthal M Sara, Shahm Manisha H, Shaha Ashok R, Tuttle R Michael, et al. *American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer.* THYROID Volume 22, Number 11, 2012. doi: 10.1089/thy.2012.0302.

Souza Rosário PW, Alvarenga Fagundes T, Villas-Boas Fagundes AS, Barroso AL, Lamego Rezende L, Lanza Padrão E, et al. *Ovarian Function After Radioiodine Therapy In Patients With Thyroid Cancer*. *Exp Clin Endocrinol Diabetes* 2005;113:331–3. doi:10.1055/s-2005-837666.

Tuttle RM, Lopez N, Leboeuf R, Minkowitz SM, Grewal R, Brokhin M, et al. *Radioactive Iodine Administered for Thyroid Remnant Ablation Following Recombinant Human Thyroid Stimulating Hormone Preparation Also Has an Important Adjuvant Therapy Function*. *Thyroid* 2010;20:257–63. doi:10.1089/thy.2009.0401.

Vuong HG, Kondo T, Duong UNP, Pham TQ, Oishi N, Mochizuki K, et al. *Prognostic Impact Of Vascular Invasion In Differentiated Thyroid Carcinoma: A Systematic Review And Meta-Analysis*. *Eur J Endocrinol* 2017;177:207–16. doi:10.1530/EJE-17-0260.

Walker F, Abramowitz L, Benabderrahmane D, Duval X, Descatoire V, Hénin D, et al. *Growth Factor Receptor Expression In Anal Squamous Lesions: Modifications Associated With Oncogenic Human Papillomavirus And Human Immunodeficiency Virus*. *Hum Pathol* 2009;40:1517–27. doi:10.1016/j.humpath.2009.05.010.

Wells Samuel A. Jr., Asa Sylvia L, Dralle Hening, Elisei Rossella, Evans Douglas B, Gagel Robert F, Nancy Lee, Machens Andreas, Moley Jeffrey F, PaciniFurio, Raue Friedhelm, Frank-Raue Karin, Robinson Bruce, Rosenthal M. Sara, Sanoro Massimo, Schlumberger Martin, Manisha Shah, Waguespack Steven G. *Revised American Thyroid Association Guidelines for the Management of Meddulary Thyroid Carcinoma*.



2015. The American Thyroid Association Guidelines Task Force on
Medullary Thyroid Carcinoma. doi :10.1089.

WHO. *World Health Organization Classification of Tumours : Pathology and
Genetics of Tumours of Endocrine Organs* 2004:50–2.

Zuber J, Tchernitsa OI, Hinzmann B, Schmitz AC, Grips M, Hellriegel M, Sers C,
Rosenthal A, Schafer R. A genome-wide survey of RAS transformation
targets. *Nat Genet* 2000 Feb;24(2):144-52. doi: 10.1038/72799